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http:WHAT THIS PAPER ADDS
Widespread community adoption of endovascular aneurysm repair (EVAR) has led to changing referral patterns
to academic centers, now consisting of more patients with unsuitable anatomy as deﬁned in the instructions for
use (IFU) of endografts. In the present study, we demonstrate that EVAR can be performed safely in high-risk
patients with unfavorable neck anatomy using commercially available endografts, and that such patients are
capable of achieving mid-term outcomes that are comparable to those achieved in patients with suitable
anatomy using a similar range of EVAR devices. Our study challenges earlier reports that EVAR outside the IFU is
associated with worse early and late clinical outcomes.Objective: Treatment of abdominal aortic aneurysms with high-risk anatomy (neck length <10e15 mm, neck
angle >60) using commercially available devices has become increasingly common with expanding institutional
experience. We examined whether placement of approved devices in short angled necks provides acceptable
durability at early and intermediate time points.
Methods: A total of 218 patients (197 men, 21 women) at a single academic center underwent endovascular
aneurysm repair (EVAR) with a commercially available device between January 2004 and December 2007.
Available medical records, pre- and postoperative imaging, and clinical follow-up were retrospectively reviewed.
Patients were divided into those with suitable anatomy (instructions for use, IFU) for EVAR and those with high-
risk anatomic aneurysm characteristics (non-IFU).
Results: IFU (n ¼ 143) patients underwent repair with Excluder (40%), AneuRx (34%), and Zenith (26%) devices,
whereas non-IFU (n ¼ 75) were preferentially treated with Zenith (57%) over Excluder (25%) and AneuRx (17%).
Demographics and medical comorbidities between the groups were similar. Operative mortality was 1.4% (2.1%
IFU, 0% non-IFU) with mean follow-up of 35 months (range 12e72). Non-IFU patients tended to have larger sac
diameters (46.7% 60 mm) with shorter (30.7% 10 mm), conical (49.3%), and more angled (68% >60) necks
(all p < .05 compared with IFU patients). Operative characteristics revealed that the non-IFU patients were more
likely to be treated utilizing suprarenal ﬁxation devices, to require placement of proximal cuffs (13.3% vs. 2.1%,
p ¼ .003), and needed increased ﬂuoroscopy time (31 vs. 25 minutes, p ¼ .02). Contrast dose was similar
between groups (IFU ¼ 118 mL, non-IFU ¼ 119 mL, p ¼ .95). There were no early or late surgical conversions.
Rates of migration, endoleak, need for reintervention, sac regression, and freedom from aneurysm-related death
were similar between the groups (p > .05).
Conclusions: EVAR may be performed safely in high-risk patients with unfavorable neck anatomy using particular
commercially available endografts. In our experience, the preferential use of active suprarenal ﬁxation and
aggressive use of proximal cuffs is associated with optimal results in these settings. Mid-term outcomes are
comparable with those achieved in patients with suitable anatomy using a similar range of EVAR devices. Careful
and mandatory long-term follow-up will be necessary to conﬁrm the beneﬁt of treating these high-risk anatomic
patients.
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Endovascular aneurysm repair (EVAR) has gained wide-
spread acceptance as the procedure of choice for patients
with infrarenal abdominal aortic aneurysms (AAAs) and
suitable aortic anatomy. Since the introduction of EVAR for
the treatment of AAA in the early 1990s,1 ongoing im-
provements in stent-graft technology and surgeon experi-
ence have emerged. Reports from individual centers
document up to 60e70% of infrarenal AAAs can be treated
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or through U.S. Food and Drug Administration (FDA)-
approved clinical trials.2,3 The enthusiasm to offer a less-
invasive procedure to patients with larger aneurysms and
multiple comorbid medical conditions is reﬂected through
nationally changing trends of aneurysm repair, with EVAR
constituting an ever-increasing proportion of elective and
emergent AAA surgery.4
Patients with unsuitable or high-risk anatomy deﬁned in
the instructions for use (IFU) of endografts are often being
referred to centers with higher volume for possible inclu-
sion in a clinical trial of a next-generation device, complex
open repair, or high-risk conventional EVAR. Anatomic
limitation is most often related to characteristics of prox-
imal neck anatomy.5 Strict inclusion criteria for entry into
clinical trials, however, often preclude these high-risk
anatomic patients from participation, and with the avail-
ability of next-generation commercially available endografts
and expanding institutional experience, EVAR with regular
devices in high-risk neck anatomy has become increasingly
common.
Particular endografts can be selected that best suit the
individual patient and tailored to aspects of compromised
neck anatomy.6 Previous reports describing EVAR outcomes
in compromised aortic neck populations are often based on
a single device as part of an institution’s involvement in a
clinical trial or growing experience or preference for one
device.3,7e9 The purpose of this current study was to
examine the mid-term results of our institutional practice
with several experienced practitioners with the unique
perspective of using three of the approved devices between
2004 and 2007, including the AneuRx (Medtronic Vascular,
Santa Rosa, CA, USA), Excluder (W.L.Gore & Associates,
Flagstaff, AZ, USA), and Zenith (Cook Medical, Bloomington,
IN, USA) endografts, in the treatment of AAAs with short
angled necks.
METHODS
Patient selection
Given the potential risks for patients undergoing EVAR
outside the IFU, ethical approval and adequate medical
supervision was obtained through our Institutional Review
Board. All patients treated electively for EVAR from January
2004 to December 2007 at a single academic center were
retrospectively identiﬁed from a prospectively maintained
clinical database. Additional patient information including
demographics, comorbidities, and outcome variables were
obtained through review of inpatient and outpatient clin-
ical records. Only patients treated with commercially
available stent-grafts with complete and accessible
anatomic and medical records were included in this anal-
ysis. Patients treated with investigational devices or
enrolled in other clinical trials were excluded from this
analysis so as to focus results on a “real world” contem-
porary academic practice without the strict guidelines set
forth in a clinical trial. We elected not to include patients
treated with investigational devices, including the Talentdevice (FDA approval, 2008), as they represent physician-
sponsored Investigational Device Exemption (IDE) data
and were published elsewhere as part of another study.
Anatomic evaluation
All available pre-, intra- and postoperative imaging was
reassessed on a 3-D workstation utilizing AquariusNET
software (TeraRecon, Inc., San Mateo, CA, USA). One sur-
geon (JTL) who was blinded to all clinical outcomes and
endograft choice on pre-op ﬁlms independently reviewed
and re-measured all radiologic data for anatomic classiﬁ-
cation. Acquired AAA anatomy included maximum trans-
verse aortic diameter at time of operative procedure and at
serial imaging time points, neck length, neck diameter, neck
angulation, neck shape, neck thrombus, maximum common
iliac diameter, associated iliac aneurysm, and iliac tortuosity.
Deﬁnitions for grading and characterization of morphologic
data are consistent with previously published criteria.10 The
imaging protocol for radiographic follow-up after EVAR
consisted of a post-procedure computed tomography-angi-
ography (CT-A), magnetic resonance (MR) imaging, and/or
Duplex ultrasound at 1 month, 6 months, and yearly
thereafter. Postoperative imaging was reviewed to evaluate
the incidence and details pertaining to device migration,
endoleak, and need for secondary intervention.
Deﬁnitions
High-risk proximal neck anatomy was deﬁned as the
following: (a) short neckda distance of <15 mm between
the most caudal renal artery and the superior aspect of the
aneurysm or (b) angulated neckdangle between the
proximal aortic neck and the longitudinal axis of the
aneurysm measuring >60. Degree of aneurysm neck
thrombus was recorded as a percentage based on the
proportion of the volume taken up by thrombus in that
segment in relation to the total volume of that aortic
segment. We subsequently stratiﬁed patients into one of
three groups based on extent of neck thrombus (mild,
<25%; moderate, 25e50%; signiﬁcant, >50%). The patient
cohort was divided into the IFU group if the proximal neck
anatomic measurements fell within manufacturer’s recom-
mendations for the endograft utilized, and the non-IFU
group if the AAA fell outside of recommended anatomic
criteria, including criteria such as aortic neck thrombus and
shape of the neck. The aorto-uniiliac (AUI) conﬁguration
used in patients with occluded iliacs or small distal aortas
was classiﬁed as outside the IFU only based on proximal
neck anatomy.
Statistics
Statistical measures included a Student t test for compari-
son of continuous variables and chi-square analysis for
comparison of categorical data. Kaplan-Meier analysis was
performed to determine overall survival and freedom from
aneurysm-related death. Signiﬁcance was deﬁned as
p < .05. Continuous data are reported as mean  standard
error or mean followed by a range when appropriate.
Table 1. Demographics and comorbidities of the EVAR cohort.
Variables IFU
(n ¼ 143)
Non-IFU
(n ¼ 75)
p
Mean age, y (range) 73.0
(52e91)
74.9
(52e91)
.26
Female sex (%) 4.9 10.7 .19
Hypertension (%) 72.0 74.7 .80
Coronary artery disease (%) 53.2 57.3 .66
Hyperlipidemia (%) 65.0 65.3 .97
Chronic renal failure (%) 16.8 16.0 .88
Type 2 diabetes (%) 18.9 14.7 .55
Congestive heart failure (%) 11.9 10.7 .96
Pulmonary disease (%) 23.8 20.0 .64
Beta-blockade therapy (%) 48.3 57.3 .26
Statin therapy (%) 63.6 54.7 .25
Coumadin therapy (%) 7.7 13.3 .27
Note. EVAR ¼ endovascular aneurysm repair; IFU ¼ instructions
for use; y ¼ years.
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analyses were performed using MedCalc version 9.2.1.0
(MedCalc Software, Ostend, Belgium).
RESULTS
Patient demographics and aneurysm morphology
Database records identiﬁed a total of 478 consecutive pa-
tients with a diagnosis of AAA treated at our institution
from January 2004 to December 2007. This time period was
selected to represent experience well after the learning
curve of EVAR for our group, as well as having several of the
currently available devices reach FDA approval. Open repair
was performed in 154 patients, whereas the remaining 324
patients underwent EVAR. The determination of whether
patients were chosen for open or endovascular AAA repair
was based on surgeon preference. Primary reasons for
elective open AAA repair included either presence of a
juxtarenal or suprarenal aneurysm or patient choice. Pa-
tients eliminated from analysis included those enrolled in a
separate Investigator Device Exemption clinical trial using
the Talent stent-graft (n ¼ 97), available to only one sur-
geon in our group, as this device was not FDA approved
during the study period. Additional patients excluded were
those patients for whom detailed anatomic and clinical in-
formation was not available (n ¼ 9) because of immediate
postoperative transfer of care. In total, the current study
group consisted of 218 patients (197 men, 21 women) with
a mean follow-up of 35 months (range 12e72).
The IFU group consisted of 143 patients, and the
remaining 75 patients, each with at least one characteristic
of high-risk neck anatomy, comprised the non-IFU group.
Non-IFU cases increased annually during the study period,
indicating increasing surgeon experience and comfort with
tackling EVAR for higher-risk anatomy. Fig. 1 displays annual
trends of both groups. Device selection was based on the
discretion of the individual surgeons and not randomized or
controlled. Patient demographics and comorbidities be-
tween the two groups were similar (Table 1). Mean pre-
operative AAA diameter was 58.5  0.7 mm, with 62.8% of
patients having aneurysm diameter 55 mm and 35.3%
with diameter 60 mm. Non-IFU patients tended to have
larger sac diameters (IFU ¼ 56.9  0.8 mm, non-Figure 1. Cumulative trends during study period between 2004
and 2007 for endovascular aneurysm repair (EVAR) repair stratiﬁed
by instructions for use (IFU) and non-IFU groups.IFU ¼ 61.5  1.3 mm, p ¼ .002) with shorter median neck
lengths (IFU ¼ 25 mm, non-IFU ¼ 13 mm, p < .05). Patients
with very short necks (neck length 10 mm) comprised
30.7% of the non-IFU group. Increased percentages of other
anatomic hostile neck features, including angulation, sig-
niﬁcant thrombus, and conical shape were also observed
within this group and are detailed in Table 2. Interestingly, a
wider neck was not observed more frequently in the non-
IFU group, indicating that our annual progression during
the study period towards treating non-IFU patients was
most often related to short (<15 mm), angulated necks. An
example of unfavorable aortic neck anatomy with a short,
angulated neck treated in this study is shown in Fig. 2.Procedural characteristics
The endograft was successfully deployed in all patients,
with bifurcated devices used in 212 patients (97.2%) and
AUI devices plus femoro-femoral bypass in six patients
(2.8%). IFU patients underwent EVAR with a roughly
equivalent distribution among approved device manufac-
turers; the Excluder device was used in 39.9% of patients,
the AneuRx device in 33.5%, and the Zenith device in 26.6%,
whereas non-IFU patients were more likely to beTable 2. Preoperative AAA measurements.
Anatomic feature IFU
(n ¼ 143)
Non-IFU
(n ¼ 75)
p
Mean AAA diameter (mm) 56.9 61.5 .002
AAA diameter 60 mm (%) 29.4 46.7 .02
Mean neck length (mm) 25.0 13.0 <.001
Neck length 10 mm (%) 0.0 30.7 <.001
Neck angle >60 (%) 0.7 68.0 <.001
Conical necks (%) 25.2 49.3 <.001
Neck diameter >28 mm (%) 4.9 12.0 .10
Signiﬁcant neck thrombus (%) 0.0 10.7 <.001
Associated iliac aneurysm (%) 25.9 22.7 .73
Signiﬁcant iliac tortuosity (%) 6.2 21.3 .002
Note. AAA ¼ abdominal aortic aneurysms; IFU ¼ instructions for
use., Neck thrombus and iliac tortuosity graded on a (0e2) scale
with a score of 2 indicating thrombus >50% and iliac angle <90.
Figure 2. Serial CT-A exams of a patient presenting with an 8.1 cm abdominal aortic aneurysm (AAA) with a 12 mm length neck and >80
angulation in a so-called “chair conﬁguration”. The patient was treated with a Zenith device and showed sac regression to 7.3 cm without
evidence of migration or endoleak in follow-up. Images are shown at (A) pre-op, (B) 1 month, (C) 6 months, (D) 1 year, (E) 2 years, and (F) 3
years post endovascular aneurysm repair (EVAR).
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the Zenith device (57.3%). Again, individual surgeons chose
devices based on preoperative anatomy and their own
preferences. There were no signiﬁcant differences noted
relative to estimated blood loss (IFU ¼ 347 mL, non-
IFU ¼ 377 mL, p ¼ .56) or amount of contrast used
(IFU ¼ 118 mL, non-IFU ¼ 119 mL, p ¼ .95) between the
two groups; however, non-IFU cases did require increased
ﬂuoroscopy time (31.3 vs. 24.7 minutes, p ¼ .02). Device
diameter was slightly larger in the non-IFU group compared
with the IFU group (IFU ¼ 26.9, non-IFU ¼ 27.8, p ¼ .04),
although, as stated before, patient neck diameter was not
signiﬁcantly different between groups. Brachiofemoral wire
pull through was employed three times in the non-IFU
group to facilitate endograft placement in the short
angled neck. Intraoperatively, ten (13.7%) patients in the
non-IFU group with severely angled necks requiredFigure 3. Intraoperative angiogram in patient with 7.5 cm AAA and 5 m
12F Cook sheath with marker angiographic catheter from contralateral
neck to aid in deployment of the main body endograft, (B) type I endo
with successful resolution of endoleak on completion angiogram.additional proximal cuff placement to successfully obtain a
seal (Fig. 3). Of note, the same manufacturer’s cuff was
placed into main body endografts when cuffs were utilized.
In comparison, only three patients in the IFU group required
proximal cuff placement, two for moderate angulation and
one for aortic tortuosity when a proximal seal was not
obtained on immediate post-deployment angiogram.Postoperative follow-up
Both EVAR cohorts showed no difference in early morbidity
and mortality (Table 3). Overall operative mortality was
2.1%, with three deaths in the 30-day perioperative period.
All deaths occurred in the IFU group. One patient was noted
to have progressive anuria on postoperative day 1 and was
found to have bilateral renal artery occlusion upon angi-
ography. Following reoperation for bilateral external iliac tom length neck treated with Zenith device demonstrating (A) use of
side placed directly within the aneurysm neck to straighten out the
leak after low main body deployment, and (C) use of proximal cuff
Table 3. Morbidity and mortality after EVAR.
Complication IFU
(n ¼ 143)
Non-IFU
(n ¼ 75)
p
30-d mortality (%) 2.1 0 .51
Overall mortality (%) 13.3 17.3 .55
All endoleak (%) 44.1 37.3 .42
Type I proximal endoleak (%) 5.6 5.3 .95
Secondary procedure (%) 7.7 9.3 .87
Graft migration (>10 mm) (%) 2.1 2.7 .79
Myocardial infarction (%) 4.9 0 .12
Stroke (%) 0.7 2.7 .57
Distal embolus (%) 3.5 0 .25
Wound management (%) 11.9 5.3 .19
Acute renal failure (%) 4.9 5.3 .89
Note. d ¼ day; EVAR ¼ endovascular aneurysm repair;
IFU ¼ instructions for use., Mean follow-up period was 34.5
months for the IFU group and 35.4 months for the non-IFU group.
J.T. Lee et al. 69renal artery bypass, the patient died as a result of
myocardial infarction on the third postoperative day. A
second patient developed an ischemic leg on postoperative
day 13 requiring reoperation for embolectomy, stent
placement, and fasciotomy. After this procedure the patient
developed pneumonia and subsequent multisystem organ
failure, ultimately expiring 15 days after endograft place-
ment. A third patient died on postoperative day 29 as a
result of myocardial infarction and congestive heart failure
exacerbation.
There were two late aneurysm-related deaths during the
follow-up period in this study, one each in the IFU and non-
IFU groups. A patient in the IFU group had initial repair with
an AUI and right iliac to left common femoral bypass that
was complicated by wound problems leading to revision of
the bypass graft and ultimately death from graft infection atFigure 4. Kaplan-Meier estimates of (A) freedom from aneurysm-relate
freedom from secondary intervention. The number of patients at risk
numbers at risk for the remaining Kaplan-Meier curves). In graphs (Be
are listed in the tables. Comparison of instructions for use (IFU) with no
estimated curves out to 3 years. Note. mo ¼ months.6 months post-EVAR. A patient in the non-IFU group died 40
months post-EVAR from renal failure and rhabdomyolysis
after a femoralefemoral bypass done for thrombosis of the
left limb of the initial endograft. Kaplan-Meier estimates of
freedom from aneurysm-related death, overall survival,
freedom from endoleak, and freedom from secondary
intervention comparing IFU and non-IFU groups (all p ¼ NS)
are shown in Fig. 4. Of note, 14 patients (6.4%) have been
lost to follow-up and have no imaging beyond 1 month
postoperatively.
All-cause secondary procedures were performed in 16.5%
of the total EVAR cohort (IFU 17.5%, non-IFU 14.7%,
p ¼ .74), with detailed interventions listed in Table 4. Initial
post-procedure imaging revealed endoleaks in 41.7% of
patients; however, overall incidence of endoleaks was
comparable between the two groups. All patients with a
proximal endoleak (two IFU vs. three non-IFU) persisting
after the 6 month evaluation were treated with an addi-
tional proximal cuff at a second procedure. One patient in
the non-IFU group required a third procedure for persistent
proximal endoleak at 33 months post-endograft placement
and had successful resolution after subsequent cuff place-
ment. Both groups showed a similar signiﬁcant decrease in
residual aneurysm sac size at last follow-up compared with
preoperative values (IFU ¼ decrease 4.9 mm, non-
IFU ¼ decrease 5.5 mm).DISCUSSION
EVAR is an established treatment for AAAs and has proven
to demonstrate excellent results in patients with suitable
anatomy over the last decade.11,12 As of 2013, there are
currently eight stent-grafts that are commercially approvedd mortality, (B) overall survival, (C) freedom from any endoleak, (D)
for each annual interval are shown in the table in graph (A) (same
D), the survival proportion along with standard error of the mean
n-IFU cohorts demonstrates no signiﬁcant differences between the
Table 4. Secondary procedures after EVAR.
Secondary procedure Number
of patients
(IFU)
Number
of patients
(non-IFU)
Total
patients
affected
Diagnostic angiogram 3 0 3
Angioplasty of limb 3 0 3
Proximal cuff 2 3 5
Distal extender 6 2 8
Coil embolization 5 2 7
Thrombectomy 4 1 5
Wound exploration 2 2 4
Pseudoaneurysm 1 0 1
Renal bypass 1 0 1
Renal stent 0 2 2
AUI conversion 1 0 1
Lower extremity bypass 1 2 3
Note. AUI ¼ aorto-uniiliac; EVAR ¼ endovascular aneurysm repair;
IFU ¼ instructions for use., Patients could have more than one
intervention performed at time of secondary procedure.
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order of FDA approval, AneuRx (Medtronic, Inc., Minneap-
olis, MN, USA), Excluder (Gore & Associates, Flagstaff, AZ,
USA), Zenith Flex (Cook Medical, Bloomington, IN, USA),
AFX endovascular system (Endologix, Inc., Irvine, CA, USA),
Talent (Medtronic, Inc.), Endurant II (Medtronic, Inc.), and
most recently in early 2013, the Ovation (TriVascular, Inc.,
Santa Rosa, CA, USA) and Aorﬁx (Lombard Medical,
Oxfordshire, UK) abdominal stent graft systems. Throughout
the evolution of this technology, proximal neck anatomy has
remained the most critical variable determining suitability
for EVAR.4 Numerous reports have described the difﬁculties
applying EVAR to aneurysms with hostile neck anatomy,
including neck angulation,7,13 neck length,5,8 associated
thrombus,2 and complex morphology.9 The short neck has
been the driving force for the development of multiple
specialized branched grafts,14 fenestrated stent-grafts,15 or
chimney/snorkel techniques.16 However, the widespread
use of such devices in the United States has been limited by
availability. Even with the recent United States FDA
approval of the Zenith Fenestrated stent-graft (Cook Med-
ical) in the summer of 2012, training issues and widespread
use of the device is still early in its dissemination. The
recent FDA approval of several newer devices and the
promising short-term results of the Nellix sac-anchoring
endoprosthesis in Europe continue to expand and reﬁne
the armamentarium of endovascular options available to
patients with unfavorable proximal neck anatomy.
In this report, we reviewed non-randomized contempo-
rary mid-term results of an academic referral practice where
over one-third of patients treated with three commercially
available endograft devices did not fall under the recom-
mended anatomic guidelines set forth by the manufacturer.
We found in this high-risk anatomic cohort that mid-term
morbidity, mortality, proximal endoleak rates, and need
for secondary interventions are similar between the IFU and
non-IFU groups. Moreover, our results are comparable with
those of highly selected patients treated in clinical trials and
in reports of single-center experiences.This study may simply demonstrate our group’s growing
experience of EVAR in hostile necks, particularly with the
increased preference for using the Zenith device and its
active suprarenal ﬁxation. In fact, 57.3% of patients in the
non-IFU group were treated with a Zenith device, as
opposed to 26.6% in the non-IFU group. Our main reason
for this preference has been in the treatment of shorter
length necks, often with associated angulation. With
increasing institutional and surgeon experience, we have
found and utilized several other features and techniques
that aid in precise placement and precision of endograft
deployment. Improved intraoperative imaging with ﬁxed
ﬂuoroscopic units in our hybrid endovascular room, next
generation lower-proﬁle and more ﬂexible delivery systems,
and more accurate preoperative 3-D evaluation of the
aneurysm neck morphology have all facilitated landing the
fabric immediately below the most caudal renal artery. For
angulated necks, a combination of stiff wires and a
contralateral sheath in the neck during deployment can be
useful in straightening the neck prior to advancement and
deployment of the main body of the device (Fig. 3A). In the
most adverse angulated necks, we have found the supra-
renal active ﬁxation and the stiffness of the proximal sealing
stent of the Zenith device to be advantageous (Fig. 2).
Adequate apposition between the stent graft and the native
aortic neck wall is essential in maintaining a circumferential
seal and reducing the risk of distal migration, endoleak, and
rupture. The IFU for the Zenith device speciﬁcally empha-
sizes molding the most proximal extent of the main body
extension with a compliant balloon. We have found routine
ballooning at the juxtarenal neck of the suprarenal barbs to
aid in our attempt to mold the suprarenal stents above a
shortened aneurysm neck, particularly when a small type I
endoleak is seen on completion angiogram.
Such aggressive maneuvers and straightening of the neck
prior to endograft proximal main body deployment should
be undertaken with experience, however, as it can lead to
adverse complications such as aortic tears and aortic
dissection. In our series, one patient experienced a distal
descending thoracic dissection as a result of wire manipu-
lation which was corrected intra-operatively with a proximal
cuff but ultimately led to distal migration of the endograft.
This was the only case of migration we noted in our series
using the Zenith graft, and our experience has suggested its
design features, namely active suprarenal hooks, are most
suitable for hostile proximal neck anatomy.
To further reduce the risk of proximal endoleaks after
EVAR for patients with unfavorable neck anatomy, other
authors have suggested the prophylactic use of Palmaz
stents.17 In our series, we preferentially used proximal
covered cuffs in order to seal type Ia endoleaks detected
either on completion angiogram or during serial follow-up
imaging (Fig. 3C). Of the 13.3% in the non-IFU group that
required an additional device placed proximally, none of
these patients in follow-up have developed subsequent
proximal endoleak. Another strategy involves the brachio-
femoral, or “body-ﬂoss”, pull through technique whereby a
through-and-through wire is placed entering the iliofemoral
J.T. Lee et al. 71vessels and exiting via the left brachial artery. This tech-
nique helps to facilitate straightening of the neck and can
also be used to overcome tortuosity in advancement of the
endograft.18 The brachiofemoral wire pull through tech-
nique can be performed with use of protective sheaths to
minimize risk of arterial injury as a result of aggressive wire
manipulation.
Mid-term results in our study are comparable when
considering the outcomes of this high-risk cohort to other
European series with even newer technology.19,20 In the
Torsello report, use of the Endurant stent-graft system
(Medtronic Vascular), has also found similar results in cases
performed outside the IFU. The active suprarenal ﬁxation is
a common theme in that series, with the current series also
demonstrating advantages of this feature. We did not gain
access to the commercially available Endurant device until
2012 and, as a result, these data are not included in the
current report. The overall 30-day operative mortality rate
in the current series was 1.4%, with all deaths occurring in
the IFU group, and is similar to that reported in a compa-
rable single-center contemporary U.S. series that utilized
the same commercially available devices.21 Our ﬁnding of
no signiﬁcant differences in the rates of migration, inci-
dence of endoleak, need for reintervention, sac regression,
and freedom from aneurysm-related death between the IFU
and non-IFU groups at 24-month follow-up is in contrast to
other studies ﬁnding increasing graft-related adverse events
and secondary interventions in endografts placed outside of
at least one IFU parameter.9,21e23
In 2006, the EUROSTAR investigators evaluated the in-
ﬂuence of infrarenal neck length on outcomes in 3499 pa-
tients undergoing EVAR with a Talent or Zenith endograft.24
Proximal type 1 endoleak occurred within 30 days in 10.9%
of patients with a neck length 10 mm compared with
2.6% in those with necks >15 mm (OR: 4.46; 95% CI: 2.61
to 7.61). A similar trend was observed at 48-month follow-
up (11.3% vs. 3.4% incidence of type 1 endoleak). More-
over, in a recent controversial report, Schanzer et al.23
reviewed postoperative imaging data from a third-party
software repository and reported on the anatomic charac-
teristics in a large patient cohort treated with EVAR be-
tween 1999 and 2008. The authors observed a 5-year post-
EVAR rate of AAA sac enlargement of 41%, with hostile neck
anatomy (speciﬁcally, aortic neck angle >60 and neck
diameter 28 mm) serving as an independent risk factor for
AAA sac enlargement. Although the implications of this
study as they pertain to the importance of patient/
anatomic selection and routine radiographic surveillance of
patients undergoing EVAR are appropriate, the authors’
warning that the liberalization of currently available
endografts beyond their IFUs is associated with worse
outcomes appears unjustiﬁed and has generated sharp
criticism as a result of several methodological ﬂaws in study
design.25e27
Two randomized controlled trials failed to detect a sur-
vival beneﬁt with early EVAR in patients with small,
asymptomatic AAAs compared with surveillance.28,29
Nevertheless, results from the CAESAR trial29 suggest thatthree out of every ﬁve small (4.0e5.5 cm) aneurysms under
surveillance may ultimately grow to require repair within 36
months, with nearly one out of every six aneurysms
potentially losing suitability for EVAR mainly as a result of
changes in proximal aortic neck morphology. With
increasing numbers of smaller aneurysms detected
following the United States Congressional approval of the
Screening Abdominal Aortic Aneurysms Very Efﬁciently
(SAAAVE) Act30 in 2007, there is the potential that the need
to deploy endografts outside the IFU might diminish over
time given that screening efforts will identify patients
earlier in the course of aneurysmal development when
anatomy is more favorable for standard EVAR. At the pre-
sent time, however, deployment of endografts outside the
IFU remains a primary strategy to expand the availability of
EVAR to patients with large AAAs and challenging aortic
neck anatomy. Possible explanations for the favorable re-
sults seen in the present study include improved institu-
tional and surgeon experience with this high-risk
population, as well as speciﬁc device selection. The much
higher percentage in the non-IFU cases of preferential use
of the Zenith device may strengthen the argument for de-
vices relying on active suprarenal ﬁxation in hostile neck
anatomy. Although our results are encouraging, longer-term
follow-up will deﬁnitely be required to determine if the
early success in the high-risk neck is sustained over time.
This retrospective study has important limitations and
the results should be interpreted cautiously. The most
obvious issue is this is not a randomized, nor even a
controlled trial of comparing inside and outside the IFU.
Simply put, these results are a reﬂection of what has
occurred in our contemporary academic practice, one that
we feel mirrors what other academic groups have seen in
recent years. In 2008, the FDA did issue a public health
notiﬁcation regarding updated data on mortality risks
associated with the use of endovascular grafts to re-
emphasize the need for continued surveillance of patients
treated with EVAR. Aneurysm-related mortality was sug-
gested to increase 3 years post-implant in the report by the
FDA, from 0.4% per year of follow-up in each of the ﬁrst 3
years, to 1.3% per year by year 4 of follow-up and 1.5% by
year 5 of follow-up, results that are substantially higher
than the mortality rate for open surgical repair at that
length of follow-up. This notiﬁcation followed earlier reports
detailing technical failures associated with the AneuRx de-
vice and prompted added scrutiny of this stent-graft system
because of its role as a currently marketed device with
signiﬁcant patients at long-term follow-up.31e33 Suboptimal
long-term results of EVAR using ﬁrst- and second-
generation commercially available stent grafts such as the
Stentor (Min-Tec, Freeport, Grand Bahama, The Bahamas)
and Vanguard (Boston Scientiﬁc Corporation, Natick, MA,
USA) endografts provided further credence toward the
development and utilization of newer devices.34,35 Although
our own results in this study offer some optimism for EVAR
in patients with anatomic constraints outside the IFU
guidelines, long-term follow-up will continue to be neces-
sary to conﬁrm the ultimate beneﬁt and durability of
72 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 1 July/2013treating these high-risk patients. In fact, we no longer
implant the AneuRx device because of this earlier warning
and, based on the results of the current study, we now
exclusively utilize devices with active suprarenal ﬁxation in
cases involving challenging neck anatomy.
An additional limitation is inherent to most retrospective
single-center reports of EVAR in that patients are lost to
follow-up, and that those that are seen with imaging may
be ones with more problems or continue to have the need
for surveillance. Finally, this non-randomized report is
biased by surgeon preference and experience being variable
even within our group and some of these results may
therefore not be generalizable to other centers or practi-
tioners. It is our assumption that, like us, most centers will
favor a primary “workhorse” endograft in situations
requiring deployment outside the IFU. We anticipate that
such centers will therefore interpret our results with their
own biases.
In summary, proximal neck anatomy continues to be the
major determinant for suitability of candidates for EVAR.
Extensive institutional experience and improved device
technology has allowed us to safely perform EVAR in high-
risk anatomic patients and obtain a proximal seal with un-
favorable neck anatomy using commercially available de-
vices. Active suprarenal ﬁxation and use of proximal cuffs
have been preferentially utilized in our patients to obtain
acceptable results. Mid-term outcomes are comparable
with those achieved in patients with standard suitable
anatomy using the same devices in our institution.
Mandatory continued follow-up of endografts of all types is
needed to justify aggressive use of standard EVAR in this
population of patients prior to routinely going outside the
IFU during EVAR.CONFLICT OF INTEREST
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